Source: Exicure, Inc. 8/7/19
Exicure, Inc. (Nasdaq: XCUR), a pioneer in gene regulatory and
immunotherapeutic drugs utilizing spherical nucleic acid (SNA™)
constructs, today announced the appointment of Dr. Bali Muralidhar, a
partner at Abingworth LLP, and Mr. Bosun Hau, a managing director and
co-head of private equity at Tybourne Capital Management, to its Board
of Directors.
“We are excited to welcome two high caliber leaders like Dr. Muralidhar
and Mr. Hau to our board,” said Dr. Chad Mirkin, Ph.D., chairman of the
board of Exicure. “Their insight and experience will greatly benefit our
strategic priorities and growth as we advance our ongoing clinical
programs and expand into new therapeutic areas.”
Bali Muralidhar, M.D., Ph.D., has more than 15 years’ experience in
healthcare across a range of functions and currently serves as partner
at Abingworth LLP, an international investment group dedicated to life
sciences. Prior to joining Abingworth, Dr. Muralidhar was a senior
partner at MVM Partners LLP. Prior to MVM, he was a member of Bain
Capital’s leverage buyout team, focusing on healthcare. He earned a
degree in clinical medicine from the University of Oxford and has a
Ph.D. in translational cancer research from the MRC Cancer Cell Unit,
University of Cambridge.
"Exicure has developed a new class of genetic medicines with a
differentiated platform for oligonucleotide drugs. The SNA technology
opens possibilities for DNA and RNA therapies in tissues other than the
liver. I am pleased to be joining the board during this important time
and to work with such a high-quality team,” said Dr. Muralidhar.
“Abingworth is delighted to have led Exicure’s recent oversubscribed
financing, which will help enable the company to advance its rich
pipeline of development candidates and bring much needed therapies to
unserved patients globally.”
Bosun Hau brings more than 15 years of life science experience to
Exicure’s board with a focus on emerging growth stage companies.
Previously, Mr. Hau served as managing director and partner at Sailing
Capital. He also served as a partner at MVM Partners and as a consultant
with McKinsey & Company. Prior to McKinsey, he was part of
GlaxoSmithKline’s corporate venture group and has also served as an
equity research analyst covering the medical device and pharmaceutical
industries for JP Morgan and Prudential. Mr. Hau received a B.S. in
Molecular and Cellular Biology, a B.S.H.S. in Physiological Sciences and
a B.A. in Psychology from the University of Arizona, an M.Sc. in
Biotechnology from Johns Hopkins University and an M.B.A in Finance and
Health Management from the Wharton School at the University of
Pennsylvania.
“I look forward to working with the Exicure board and management team to
bring additional strategic perspective to their pipeline and advance
innovative drug candidates from discovery through development to benefit
patients,” said Mr. Hau.
About Exicure, Inc.
Exicure, Inc. is a clinical-stage biotechnology company
developing therapeutics for immuno-oncology, inflammatory diseases and
genetic disorders based on our proprietary Spherical Nucleic Acid, or
SNA technology. Exicure believes that its proprietary SNA architecture
has distinct chemical and biological properties that may provide
advantages over other nucleic acid therapeutics and may have therapeutic
potential to target diseases not typically addressed with other nucleic
acid therapeutics. Exicure's lead program is in a Phase 1b/2 trial in
patients with advanced solid tumors. Exicure is based outside of
Chicago, IL and in Cambridge, MA. www.exicuretx.com
No comments:
Post a Comment